Global Hepatitis B Vaccines Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Hepatitis B Vaccines Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.

According to our (Global Info Research) latest study, the global Hepatitis B Vaccines market size was valued at US$ 1306 million in 2023 and is forecast to a readjusted size of USD 2025 million by 2030 with a CAGR of 6.3% during review period.

Global key players of Hepatitis B Vaccines include GSK, Dynavax, NCPC, etc. The top three players hold a share about 65%. North America is the largest market, and has a share about 45%, followed by Asia-Pacific and Europe with share 31% and 17%, separately. In terms of product type, Yeast Derived is the largest segment, occupied for a share of 85%. In terms of application, Adult is the largest field with a share about 64 percent.

This report is a detailed and comprehensive analysis for global Hepatitis B Vaccines market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Hepatitis B Vaccines market size and forecasts, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (US$/Dose), 2019-2030

Global Hepatitis B Vaccines market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (US$/Dose), 2019-2030

Global Hepatitis B Vaccines market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (US$/Dose), 2019-2030

Global Hepatitis B Vaccines market shares of main players, shipments in revenue ($ Million), sales quantity (M Doses), and ASP (US$/Dose), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Hepatitis B Vaccines

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Hepatitis B Vaccines market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, NCPC, Merck, Bio Kangtai, Dynavax, AIM Vaccine, KM Biologics, LG Life Sciences, Serum Institute, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Hepatitis B Vaccines market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Yeast Derived
CHO Derived

Market segment by Application
Children
Adult

Major players covered
GSK
NCPC
Merck
Bio Kangtai
Dynavax
AIM Vaccine
KM Biologics
LG Life Sciences
Serum Institute

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Hepatitis B Vaccines product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Hepatitis B Vaccines, with price, sales quantity, revenue, and global market share of Hepatitis B Vaccines from 2019 to 2024.

Chapter 3, the Hepatitis B Vaccines competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Hepatitis B Vaccines breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Hepatitis B Vaccines market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Hepatitis B Vaccines.

Chapter 14 and 15, to describe Hepatitis B Vaccines sales channel, distributors, customers, research findings and conclusion.